CGI Pharmaceuticals
Founded in 2001, CGI Pharmaceuticals was a development-stage company focused on small molecule chemistry and kinase biology. CGI generated a library of proprietary, small molecule kinase inhibitors. The company’s lead preclinical compound targeted the spleen and could have applications for inflammatory disease, such as rheumatoid arthritis. In 2010, Gilead acquired CGI for $120M.
